A new peer-reviewed research study, published in the American Journal of Therapeutics, claims that regular use of the drug, Ivermectin, significantly protects against contracting COVID-19.
The study compiled and analyzed data from several recently published peer-reviewed research papers.
“Meta-analyses based on 18 randomized controlled treatment trials of Ivermectin in COVID-19 have found large, statistically significant reductions in mortality, time to clinical recovery, and time to viral clearance,” the study states.
Co-author, Paul E. Marik, professor of Medicine and Chief of Pulmonary and Critical Care Medicine at Eastern Virginia Medical School said in a recent statement that the “latest research shows, once again, that when the totality of the evidence is examined, there is no doubt that Ivermectin is highly effective as a safe prophylaxis and treatment for COVID-19.”
Marik added, “We are calling on regional public health authorities and medical professionals around the world to demand that Ivermectin be included in their standard of care right away so we can end this pandemic once and for all.”
This published research comes at the same time as a controversial ruling which ruled in favor of a 68 year-old, Chicago woman who demanded she be administered Ivermectin after being hospitalized with COVID-19.
According to NBC5 Chicago, the woman’s daughter said Tuesday, “She looks calm, comfortable, and I’m happy with her monitor numbers so far. They are kind of stable.”
Ivermectin has been approved for use by the FDA as an anti-parasite drug. In March, the FDA warned against using Ivermectin to treat COVID-19, stating that there was not enough information to support or refute claims of its efficacy against the virus.